Fundai

Sobhan Pharmaceutical Group (DSOBHA) income statement

Operating revenue through to net profit and earnings per share

Ticker
DSOBHA
Industry
Pharmaceuticals
Market
Tehran Stock Exchange

Latest periods

Latest 6-month periods, in million rials
ItemTo 1405/06/31To 1404/06/31To 1403/06/31To 1402/06/31To 1401/06/31
درآمد سود سهام5,29659,39954,54594,62335,446
Total operating revenue5,29659,39954,54594,62335,446
هزینه های حقوق، دستمزد و مزایا-83,390-58,759-41,946-70,527-61,157
Depreciation expense-1,737-410-285--
Other expenses-105,141-49,390-44,52900
جمع هزینه های عملیاتی-190,268-108,559-90,780-70,527-61,157
Operating profit (loss)-184,972-49,160-36,23524,096-25,711
Finance costs-152,523-184,216-130,902-109,3920
Other non-operating income and expenses171,24176,555277,169701,653858,951
Profit (loss) from continuing operations before tax-166,254-156,821110,032616,357833,240
Net profit (loss) from continuing operations-166,254-156,821110,032616,357833,240
Net profit (loss)-166,254-156,821110,032616,357833,240
Operating (rials)-13-7-54-8
Non-operating (rials)1-162186266
Arising from continuing operations-12-2316--
سود (زیان) پایه هر سهم (ریال)-12 rials-23 rials16 rials90 rials258 rials
سود (زیان) خالص هر سهم (ریال)-11 rials-22 rials16 rials89 rials120 rials
Capital14,521,0006,975,0006,975,0006,975,0006,975,000

Reporting periods

37 periods are on file for this report, from the period ending 1388/06/31 to the period ending 1405/06/31.